Abstract Library

#4297 Small bowel neuroendocrine neoplasm – A very intriguing case

Introduction: Functional neuroendocrine neoplasms (NEN) frequently result in a range of severe and unpleasant symptoms and can also result in life threatening illness. This case report will detail the complex history of a patient with metastatic small bowel tumour diagnosed in 2015 with current stable disease treated at the West of Scotland Cancer Centre.

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: Neuroendocrine cancer, Complexity, Life threatening complications,

#4295 Are patients on somatostatin analogue therapy receiving high quality holistic cancer nursing care?

Introduction: SSA is indicated for the treatment of G1 and some G2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin in adult patients with unresectable locally advanced or metastatic disease. As these types of cancer have much lower proliferation rates than common cancers, they are not exclusively considered cancer. It is hypothesised these patients may subsequently receive sub-standard cancer care. Furthermore, patients who are diagnosed with metastatic G3 neuroendocrine cancers will require systemic treatment with significant side effect profiles impacting negatively on quality of life.

Conference:

Presenting Author:

Authors: Wotherspoon I,

Keywords: Cancer nursing,

#4294 Measuring quality of life in patients receiving radionuclide therapy using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and Gastro-intestinal NET (GINET) 21

Introduction: Neuroendocrine tumours over express somatostatin receptors on the cell surface. These receptors can be targeted by radiation via Peptide Receptor Radionuclide Therapy (PRRT). NETTER 01 trial demonstrated excellent results in progression-free survival. Scottish National service commenced April 2019 at Beatson West of Scotland Cancer Centre. Service Level Agreement to submit multiple metrics including Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM). EORTC QLQ 30 and GI NET 21 validated research tools which are used to measure outcomes.

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: EORTC 30 QLQ with the GINET 21 module,

#4116 A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

Introduction: Scottish National PRRT Service delivers 177Lu-Dotatate nationally at the Beatson West of Scotland Cancer Centre (BWoSCC). The NETTER-1 trial (Strosberg et al 2017) significantly changed the treatment and management of patients with gastroenteropancreatic NET (GEPNET). 177Lu-Dotatate demonstrated superiority in progression free survival (PFS) in patients with G1 and 2 midgut neuroendocrine tumors (NET). 177Lu-Dotatate 7.4 GBq 8 weekly gave 65% estimated progression free survival (PFS)at 20 months versus 10.8 % with 60mg octreotide intramuscularly 4 weekly (Strosberg et al 2017). Prior to this study everolimus was the most common 2nd line treatment for SBNET with a PFS of 14 months (Puscuddo et al 2017).

Conference:

Presenting Author:

Authors: Wotherspoon I, Charlick A, McIntosh D, Reed N,

Keywords: NETTER-1, Scottish PRRT Service,